特此公告 关于变更保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"） 于近日收到公司首次 公开发行股票并在创业板上市的保荐机构中信建投证券股份有限公司（以下简称 "中信建投"）出具的《中信建投证券股份有限公司关于变更山东三元生物科技 股份有限公司首次公开发行股票项目持续督导保荐代表人的函》，原保荐代表人 陈磊先生因工作变动原因，不再负责公司首次公开发行股票并在创业板上市的持 续督导保荐工作。 为保证公司持续督导工作的有序进行，中信建投委派邵路伟先生（简历详见 附件）接替陈磊先生担任公司持续督导保荐代表人，继续履行相关职责。本次保 荐代表人变更后，公司持续督导期保荐代表人为邵路伟先生和张现良先生。持续 督导期至 2025 年 12 月 31 日止。 公司董事会对陈磊先生在公司首次公开发行股票项目保荐发行及持续督导 期间所做的贡献表示衷心的感谢。 证券代码：301206 证券简称：三元生物 公告编号：2025-088 山东三元生物科技股份有限公司 山东三元生物科技股份有限公司 董事会 2025 年 1 ...

Group 1: Core Insights - The financing of listed companies in the sugar substitute industry primarily aims to enhance production capacity [1] - The majority of external investments by representative companies focus on expanding upstream and downstream operations [1][6] Group 2: Financing and Investment - The main financing methods for listed companies include IPOs, private placements, and convertible bonds, with a focus on new projects and capacity enhancement [1] - Notable external investments include significant amounts such as 100 million RMB by Sanyuan Bio and 10 million RMB by Hainan Baolijian [2][3][4] Group 3: Industry Parks and Development - The number of sugar substitute industrial parks in China is limited, with major parks located in Shandong, which is recognized as a global production base [7][8] - The Dezhou High-tech Zone in Shandong has a production capacity of 1.5 million tons and a domestic market share of over 70% [8] Group 4: Mergers and Acquisitions - Recent mergers and acquisitions in the sugar substitute industry are primarily driven by midstream companies seeking to expand scale and secure upstream resources [9][12] - Key acquisitions include Huakang's purchase of Henan Yuxin Sugar Alcohol Co. for 1.098 billion RMB, aimed at increasing market share [12]

Core Insights - The trend of young consumers moving away from "sugar-free" products is evident, with a noticeable slowdown in the growth of sugar-free tea sales and a decline in the popularity of sugar substitutes [5][12][14] Industry Overview - Sugar-free tea sales growth has significantly decreased, with sales growth rates from April to September 2023 being 3.9%, 7%, 19.9%, 19.5%, 8.5%, and 6.3%, all lower than the same periods in the previous year [2] - The average price of sugar-free tea has been on the rise, increasing from 5.1 yuan per piece in 2023 to 5.6 yuan per piece by 2025, indicating that despite higher prices, total sales growth is slowing [2] - The market is dominated by established brands like Nongfu Spring and Suntory, which together hold 87.3% market share as of September 2023, up 6.4% from the previous year [7] - The second-tier brands' market share has decreased from 11.3% to 7.4%, while the third-tier brands' share has shrunk from 5.1% to 3.4%, highlighting the intensifying head effect in the industry [7][9] Consumer Behavior - The shift in consumer preferences indicates that the younger generation is moving away from extreme health consciousness towards a more indulgent lifestyle, seeking comfort in sugary beverages [5][12] - The demand for sugar substitutes, particularly erythritol, has also faced challenges, with a reported oversupply in the market as of May 2023, where domestic production capacity reached 380,000 tons per year against a global demand of only 173,000 tons [2][14] Product Innovation - There has been a lack of new hit products in the sugar-free tea market, with established products like unsweetened oolong and jasmine tea dominating nearly 70% of the market share [9] - The innovation in the sugar-free tea sector has stagnated, with brands focusing on minor innovations around existing products rather than developing new ones, leading to potential homogenization and price competition [9][11] - In contrast, the sugary tea segment has seen a surge in new product launches, with sugary tea products outnumbering sugar-free tea products significantly in recent months [10] Supplier Challenges - Suppliers of sugar substitutes are experiencing significant operational pressures, with major companies like San Yuan Bio reporting a 7.54% decline in total revenue and a 16.8% drop in net profit for the first three quarters of the year [14][19] - The industry is facing a broader trend of declining demand, leading to increased competition and financial strain on suppliers, many of whom are exploring alternative products and markets to mitigate losses [17][19]

Core Viewpoint - The company has legally obtained the production license for allulose and is currently supplying it steadily to domestic customers [2] Group 1 - The company has acquired the production license for allulose, indicating compliance with regulatory requirements [2] - The company is actively supplying allulose to domestic clients, suggesting a stable market presence [2]

Core Viewpoint - Sanwei Biological has legally obtained the production license for allulose and is currently supplying the product steadily to domestic customers [1] Company Summary - Sanwei Biological (301206.SZ) has successfully acquired the production license for allulose, indicating a significant step in its operational capabilities [1] - The company is now actively supplying allulose to domestic clients, which may enhance its market presence and revenue potential [1]

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于山东三元生物科技股份有限公司 2025 年第五次临时股东会的 法律意见书 国枫律股字[2025]A0542 号 致：山东三元生物科技股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2025 年第五次临时股东会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律 业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法 律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《山东三元生物科技 股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程 序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜 ...

证券代码：301206 证券简称：三元生物 公告编号：2025-087 山东三元生物科技股份有限公司 2025 年第五次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形。 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 现场会议时间：2025 年 11 月 12 日（星期三）15:00 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025 年 11 月 12 日 9:15—9:25，9:30—11:30 和 13:00—15:00；通过深圳证券交易 所互联网投票系统的具体时间为：2025 年 11 月 12 日 9:15 至 15:00 2、会议召开地点：山东省滨州市滨北梧桐十路 101 号三元生物公司会议室 3、会议召开方式：现场投票和网络投票相结合的方式 通过现场和网络投票的中小股东 140 人，代表股份 1,230,709 股，占公司有 表决权股份总数的 0.6154%。 4、会议召集人：董事会 5、 ...

Core Viewpoint - San Yuan Bio provided information regarding the specifics of "construction in progress" and its monetary changes, directing investors to refer to the company's "2025 Semi-Annual Report" for detailed financial statements and notes [2] Group 1 - The company addressed investor inquiries on its interactive platform regarding the composition and monetary changes of "construction in progress" [2] - Investors are advised to consult the "Section 8 Financial Report" and "Note 12: Construction in Progress" in the company's upcoming semi-annual report for detailed information [2]

证券代码：301206 证券简称：三元生物 公告编号：2025-086 山东三元生物科技股份有限公司 公司于近日收到股东鲁信资本出具的《关于股份减持计划期满暨实施结果的 告知函》，截至本公告日，上述减持计划已期限届满，现将有关情况公告如下： 一、股东股份减持计划实施情况 | 股东 名称 | 减持方式 | | 减持期间 | | | 减持均价 （元/股） | 减持股数 （股） | 减持比例 （%） | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 大宗交易 | 2025 -2025 | 年 8 年 10 | 月 月 | 7 日 日 29 | 29.35 | 4,000,000 | 2.000% | | 鲁信 资本 | 集中竞价 | 2025 | 年 8 | 月 | 7 日 | 29.27 | 1,990,050 | | | | | -2025 | 年 10 | 月 | 日 29 | | | 0.995% | | | 合计 | | - | | | - | 5,990,050 | 2.995% | （一）股东减持股份情况 1 / 3 注 1、上 ...

Core Viewpoint - The announcement from San Yuan Bio indicates that shareholder Luxin Capital has completed its share reduction plan, which involved a total reduction of approximately 599,005 shares, representing about 2.995% of the total share capital [1] Summary by Sections Shareholder Reduction Plan - Luxin Capital originally planned to reduce its holdings by up to 6 million shares, or 3% of the total share capital, starting from a specific date in 2025 [1] - As of the announcement date, Luxin Capital executed the reduction between August 7 and October 29, 2025, through block trades and centralized bidding [1] Reduction Details - The total shares reduced included 400,000 shares through block trades and 199,005 shares through centralized bidding, culminating in a total of 599,005 shares [1] - Following the reduction, Luxin Capital's holdings decreased to 193,000 shares, which is 0.97% of the total share capital [1] Impact on Company - The share reduction did not result in a change of control for the company and is not expected to have a significant impact on its operations [1]